A Prospective Controlled Study of Serum suPAR in the CsA-treated FSGS Patients

Guangdong Provincial People's Hospital90 enrolled

Overview

The purpose of this study is to determine whether the improved responsiveness to treatment achieved by CsA in patients with steroid-resistant or steroid-dependent FSGS could be explained by CsA's inhibitory action on the circulating suPAR expression.

Study Type

OBSERVATIONAL

Enrollment

Conditions

FSGS

Eligibility

Sex: ALLMin age: 14 YearsMax age: 70 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Age at entry is between 14 and 70 years * biopsy-proven primary FSGS * proteinuria \>=3 g/day * without corticosteroids or CsA treatment before entry Exclusion Criteria: * Chronic Inflammatory Diseases * malignant tumor * diabetes mellitus * contraindications for the treatment of corticosteroids or CsA treatment * untolerate to or unwilling to accept corticosteroids or CsA treatment

Locations (1)

Nephrology Dept.,Guangdong General Hospital

Guangzhou, Guangdong, China

RECRUITING

Outcomes

Primary Outcomes

serum suPAR level when proteinuria reduction >=50% or complete remission

serum suPAR level when proteinuria reduction of \>=50% or complete remission occurs within \<=6 months of steroid alone or CsA plus steroid treatment

Time frame: 6 months after steriod alone or CsA plus steriod treatment

Secondary Outcomes

serum suPAR level after 6 months of steroid or CsA treatment without remission

serum suPAR level after 6 months of steroid alone or CsA plus steroid treatment without remission

Time frame: 6 months after steroid alone or CsA plus steroid treatment

Central Contacts

Wei Shi, MD,PhD

CONTACT

86-20-8385-0849 weishi_gz@126.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.